No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
GSK Announces Positive Interim Results for Blenrep® Combination Therapy
On 14 November 2024, GlaxoSmithKline (GSK) announced positive results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) as a second-line or...